

## **Innovation 4 Society report – Janssen Nederland - Summary**

**The past year has underscored the importance of well-organized healthcare and innovation in the field of medicines and vaccines. The development of corona vaccines within a year of the pandemic outbreak was possible thanks to collaboration. Joint efforts between governments, universities, hospitals and companies are the key to success. In all the areas where we want to make a difference for patients, we invest in both building on existing collaborations and entering new ones.**

Indispensable ingredients for cooperation are mutual understanding and trust. We invite you, the reader, to gain more insight into who we are and what we do through this report. From the development, production and availability of medicines and vaccines, to our commitment, together with our partners to improve care for patients in the Netherlands. In this year's issue, we pay particular attention to the development and production of our vaccine against covid-19. We illustrate this with recent data and concrete examples.

### **Working towards a future in which diseases are a thing of the past**

Janssen is a major employer and investor in the Netherlands. We work with more than 2,700 dedicated colleagues at three locations, Janssen Vaccines, Janssen Biologics and Janssen-Cilag, which together form the "Janssen Campus Netherlands". A large proportion of these colleagues (over 1100) work in research and development, a branch in which we invested €499 million in 2020. This makes Janssen the third largest private investor in R&D in the Netherlands. The development of the COVID-19 vaccine in Leiden is a telling example of what such investments can lead to.

Vaccines deliver enormous health benefits. But it is also thanks to new, innovative medicines that the chances of survival of people with serious diseases have greatly improved in recent decades. In many cases, this also applies to the improved quality of life for patients, which is always central for us and guides our innovations. We therefore work with patients and patient organizations such as Hiv Vereniging Nederland, Crohn & Colitis Nederland and Lung Cancer Nederland to understand what is really important to patients. This knowledge benefits the entire development process of our medicines.

### **Working together on meaningful innovations**

The path a molecule takes from discovery in the lab to the application as a drug for patients is long and uncertain. On average, the development of a drug takes 12-13 years, and of the thousands of compounds being studied, only a few reach the patient. This does not mean that the effort was wasted: even if research does not lead directly to a new drug, we gain new knowledge about diseases and how to combat them. This contributes, for example, to the development of *personalized medicine*, which are treatments that are increasingly tailored to the individual patient. Moreover, drug development is becoming increasingly efficient thanks to large data sets and *machine learning*.

To accelerate innovations in these areas, we actively seek collaboration – this is the core of our strategy. We do this in large consortia and as smaller collaborations. In September 2020, for example, we signed a partnership with Leiden University and the Leiden University Medical Center, our academic neighbors at the Leiden Bioscience Park, and with JLABS (Johnson & Johnson Innovation) we accelerate innovations at startups.

## **Leiden's vaccine development**

We are particularly proud of the development of our COVID-19 vaccine, which largely took place in the Netherlands. From the moment the genetic code of the coronavirus became known in January 2020, our researchers in Leiden worked hard to research a potential vaccine against COVID-19. Here too, collaboration played an important role: together with hospitals and governments around the world, we were able to conduct clinical trials among tens of thousands of volunteers in a short period of time. Long before the first results of this vaccine research were known, our production organization Janssen Biologics made plans to produce this vaccine on large scale. The production capacity in Leiden had to be expanded significantly for this purpose: we therefore built a new production facility and took on approximately 200 new employees in one year. In August 2020, we started the production of the first batch of the active ingredient for our COVID-19 vaccine in the existing facilities, and in June 2021, we commissioned the expansion of the vaccine factory.

## **The future of healthcare**

Janssen's contribution to the fight against COVID-19 is an illustration of the important role that innovative companies play for public health. At the same time, we are aware of the social debate concerning expenditure on innovative medicines. In this report, we provide insight into how we bring our medicines onto the market and our basic principle in this respect: to get our medicines to the patient as quickly as possible, and at a fair price.

Nevertheless, the Dutch healthcare system faces challenges. Expenditure on medicines accounts for a relatively small proportion of the total Dutch healthcare budget and is below the European average. Despite this, total healthcare costs are rising every year, as is spending on medicines. To keep good care affordable, we need to focus on the outcomes of the care provided. By optimizing the relationship between the costs and outcomes of care in daily practice, we increase the quality and efficiency of care as a whole. In this way, we are working on the care of the future.